<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommended antimicrobial prophylaxis for urologic procedures</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommended antimicrobial prophylaxis for urologic procedures</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommended antimicrobial prophylaxis for urologic procedures</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Procedure</td> <td class="subtitle1">Likely organisms</td> <td class="subtitle1">Prophylaxis indicated</td> <td class="subtitle1">Antimicrobial(s) of choice</td> <td class="subtitle1">Alternative antimicrobial(s), if required</td> <td class="subtitle1">Duration of therapy*</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Lower tract instrumentation</td> </tr> <tr> <td class="indent1">Cystourethroscopy with minor manipulation, break in mucosal barriers, biopsy, fulguration, etc; clean-contaminated</td> <td>GNR, rarely enterococci<sup>¶</sup></td> <td>Uncertain<sup>Δ</sup>; consider host-related risk factors. Increasing invasiveness increases risk of SSI.</td> <td>TMP-SMX, amoxicillin/clavulanate</td> <td>First/second-generation cephalosporin + aminoglycoside (aztreonam<sup>◊</sup>) ± ampicillin</td> <td>Single dose</td> </tr> <tr> <td class="indent1">Transurethral cases (eg, TURP, TURBT, laser enucleative and ablative procedures, etc); clean-contaminated<sup>§</sup></td> <td>GNR, rarely enterococci</td> <td>All cases</td> <td>Cefazolin, TMP-SMX</td> <td>Amoxicillin/clavulanate, aminoglycoside (aztreonam<sup>◊</sup>) ± ampicillin</td> <td>Single dose</td> </tr> <tr> <td class="indent1">Prostate brachytherapy or cryotherapy; clean-contaminated</td> <td><em>Staphylococcus aureus</em>, skin; GNR</td> <td>All cases</td> <td>Cefazolin</td> <td>Clindamycin<sup>¥</sup></td> <td>Single dose</td> </tr> <tr class="divider_bottom"> <td class="indent1">Transrectal prostate biopsy; contaminated</td> <td>GNR, anaerobes<sup>‡</sup>; consider MDR coverage, if risks of systemic antibiotics within six months, international travel, health care worker</td> <td>All cases</td> <td>Fluoroquinolone, first/second/third-generation cephalosporin (ceftriaxone commonly used) + aminoglycoside</td> <td> <p>Aztreonam</p> May need to consider ID consultation</td> <td>Single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Upper tract instrumentation</td> </tr> <tr> <td class="indent1">Percutaneous kidney surgery (eg, PCNL); clean-contaminated</td> <td>GNR, rarely enterococci, and skin<sup>†</sup>, <em>S. aureus</em></td> <td>All cases</td> <td>First/second-generation cephalosporin, aminoglycoside (aztreonam<sup>◊</sup>) + metronidazole, or clindamycin</td> <td>Ampicillin/sulbactam</td> <td>≤24 hours</td> </tr> <tr class="divider_bottom"> <td class="indent1">Ureteroscopy, all indications; clean-contaminated</td> <td>GNR, rarely enterococci</td> <td>All cases; of undetermined benefit for uncomplicated, diagnostic-only procedures</td> <td>TMP-SMX, first/second-generation cephalosporin</td> <td>Aminoglycoside (aztreonam<sup>◊</sup>) ± ampicillin, first/second-generation cephalosporin, amoxicillin/clavulanate</td> <td>Single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Open, laparoscopic, or robotic surgery</td> </tr> <tr> <td class="indent1">Without entering urinary tract (eg, adrenalectomy, lymphadenectomy, retroperitoneal or pelvic); clean</td> <td><em>S. aureus</em>, skin</td> <td>Consider in all cases; may not be required</td> <td>Cefazolin</td> <td>Clindamycin</td> <td>Single dose</td> </tr> <tr> <td class="indent1">Penile surgery (eg, circumcision, penile biopsy, etc); clean-contaminated</td> <td><em>S. aureus</em></td> <td>Likely not required</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Urethroplasty; reconstruction of the anterior urethra; stricture repair, including urethrectomy; clean; contaminated; controlled entry into the urinary tract</td> <td>GNR, rarely enterococci, <em>S. aureus</em></td> <td>Likely required</td> <td>Cefazolin</td> <td>Cefoxitin, cefotetan, ampicillin/sulbactam</td> <td>Single dose</td> </tr> <tr> <td class="indent1">Involving controlled entry into urinary tract (eg, kidney surgery; nephrectomy, partial or otherwise; ureterectomy; pyeloplasty; radical prostatectomy); partial cystectomy, etc; clean-contaminated</td> <td>GNR (<em>Escherichia coli</em>), rarely enterococci</td> <td>All cases</td> <td>Cefazolin, TMP-SMX</td> <td>Ampicillin/sulbactam, aminoglycoside (aztreonam<sup>◊</sup>) + metronidazole, or clindamycin</td> <td>Single dose</td> </tr> <tr> <td class="indent1">Involving small bowel (ie, urinary diversions, cystectomy with small bowel conduit, other GU procedures); ureteropelvic junction repair, partial cystectomy, etc; clean-contaminated</td> <td>Skin, <em>S. aureus</em>, GNR, rarely enterococci</td> <td>All cases</td> <td>Cefazolin</td> <td>Clindamycin and aminoglycoside, cefuroxime (second-generation cephalosporin), aminopenicillin combined with a beta-lactamase inhibitor + metronidazole</td> <td>Single dose</td> </tr> <tr> <td class="indent1">Involving large bowel**; colon conduits; clean-contaminated</td> <td>GNR, anaerobes</td> <td>All cases</td> <td> <p>Cefazolin + metronidazole, cefoxitin, cefotetan, or ceftriaxone + metronidazole, ertapenem</p> NB: These IV agents are used along with mechanical bowel preparation and oral antimicrobial (neomycin sulfate + erythromycin base or neomycin sulfate + metronidazole)</td> <td>Ampicillin/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam</td> <td>Single parenteral dose</td> </tr> <tr> <td class="indent1">Implanted prosthetic devices: AUS, IPP, sacral neuromodulators; clean</td> <td>GNR, <em>S. aureus</em>, with increasing reports of anaerobic and fungal organisms</td> <td>All cases</td> <td>Aminoglycoside (aztreonam<sup>◊</sup>) + first/second-generation cephalosporin or vancomycin<sup>¶¶</sup></td> <td>Aminopenicillin beta-lactamase inhibitor, including ampicillin/sulbactam, ticarcillin, or tazobactam</td> <td>≤24 hours</td> </tr> <tr> <td class="indent1">Inguinal and scrotal cases (eg, radical orchiectomy, vasectomy, reversals, varicocelectomy, hydrocelectomy, etc); clean</td> <td>GNR, <em>S. aureus</em></td> <td>Of increased risk; all cases</td> <td>Cefazolin</td> <td>Ampicillin/sulbactam</td> <td>Single dose</td> </tr> <tr class="divider_bottom"> <td class="indent1">Vaginal surgery, female incontinence (eg, urethral sling procedures, fistulae repair, urethral diverticulectomy, etc); clean-contaminated</td> <td><em>S. aureus</em>, streptococci, enterococci, vaginal anaerobes; skin</td> <td>All</td> <td>Second-generation cephalosporin (cefoxitin, cefotetan) provides better anaerobic coverage than first-generation cephalosporins; however, cefazolin is equivalent coverage for the vaginal anaerobes in sling procedures</td> <td>Ampicillin/sulbactam + aminoglycoside (aztreonam<sup>◊</sup>) + metronidazole, or clindamycin</td> <td>Single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Other</td> </tr> <tr> <td class="indent1">Shock-wave lithotripsy; clean</td> <td>GNR, rarely enterococci; GU pathogens</td> <td>Only if risk factors</td> <td>If risks, consider TMP-SMX, first-generation cephalosporin (cefazolin), second-generation cephalosporin (cefuroxime), aminopenicillin combined with a beta-lactamase inhibitor + metronidazole</td> <td>First/second-generation cephalosporin, amoxicillin/clavulanate, ampicillin + aminoglycoside (aztreonam<sup>◊</sup>), clindamycin</td> <td>Single dose</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>GNR: gram-negative rod; SSI: surgical site infection; TMP-SMX: sulfamethoxazole and trimethoprim; TURP: transurethral resection of the prostate; TURBT: transurethral resection of bladder tumor; MDR: multidrug resistant; ID: infectious diseases; PCNL: percutaneous nephrolithotomy; GU: genitourinary; IV: intravenous; AUS: artificial genitourinary sphincter; IPP: implantable penile prosthesis; GPC: gram-positive cocci; AP: antimicrobial prophylaxis.</p>
<p>* Or full course of culture-directed antimicrobials for documented infection (which is treatment, not prophylaxis).</p>
<p>¶ GU GNR: Common urinary tract organisms are <em>E. coli</em>, <em>Proteus</em> spp, <em>Klebsiella</em> spp, and GPC <em>Enterococcus</em>.</p>
<p>Δ If urine culture shows no growth prior to the procedure, antimicrobial prophylaxis is not necessary.</p>
<p>◊ Aztreonam can be substituted for aminoglycosides in patients with kidney function impairment.</p>
<p>§ Includes transurethral resection of bladder tumor and prostate and any biopsy, resection, fulguration, foreign body removal, urethral dilation or urethrotomy, or ureteral instrumentation including catheterization or stent placement/removal.</p>
<p>¥ Clindamycin, or aminoglycoside + metronidazole or clindamycin, are general alternatives to penicillins and cephalosporins in patients with penicillin allergy, even when not specifically listed.</p>
<p>‡ Intestine: Common intestinal organisms include aerobes and anaerobes: <em>E. coli</em>, <em>Klebsiella</em> spp, <em>Enterobacter</em>, <em>Serratia</em> spp, <em>Proteus</em> spp, <em>Enterococcus</em>, and <em>Anaerobes</em>.</p>
<p>† Skin: Common skin organisms are <em>S. aureus</em>, coagulase-negative <em>Staphylococcus</em> spp, Group A <em>Streptococcus</em> spp.</p>
<p>** For surgery involving the colorectum, bowel preparation with oral neomycin plus either erythromycin base or metronidazole is added to systemic agents.</p>
¶¶ Routine administration of vancomycin for AP is not recommended. The antimicrobial spectrum of vancomycin is less effective against methicillin-sensitive strains of <em>S. aureus</em>.</div><div class="graphic_reference">From: Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol 2020; 203:351. DOI: <a href="https://www.auajournals.org/doi/10.1097/JU.0000000000000509" target="_blank">10.1097/JU.0000000000000509</a>. Copyright © 2020 American Urological Association. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 129971 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
